Related Experiment Video
Updated: Nov 25, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider
Mary A Hatch-Maillette1, K Michelle Peavy2, Judith I Tsui3
1Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA 98105, United States of America; Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, United States of America.
Abstract:
COVID-19 necessitated rapid changes in methadone take-home policies in opioid treatment programs (OTPs); these changes markedly contrast with existing, long-standing federal mandates on OTP rules about take-home methadone. OTP providers describe how these changes have affected clinical decision-making, equity in patient care, and workflow. We also discuss implications for medical ethics and patient autonomy. We provide suggestions for future research that will examine the impact of COVID-19 on OTP treatment and its patients, as well as the effect of making methadone take-home polices patient centered, all of which may foreshadow larger changes in the ways OTPs deliver their services.
More Related Videos
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Therapeutic Drug Monitoring: Affecting Factors
Drug Therapy
Antianxiety Medications
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners

